…. which would bring it to market earlier. Great news if it works, lets wait and see the SVR figures before we get too excited though.
Wall Street analysts still have high hopes for VX-950, a developmental-stage treatment for hepatitis C. Sales of VX-950 are expected to peak at $1.4 billion in 2011, according to McDonald.
The […]

Another one hits the “track”.
Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment of chronic hepatitis […]

NM283 is another drug in trials that is showing some positive results with the hard to treat genotype 1 Hepatitis C. You know the drill, years away if ever but still worth keeping an eye on.
Idenix Pharmaceuticals announced 4-week data today from an ongoing phase IIb clinical trial demonstrating that treatment with valopicitabine NM […]

The Vertex VX-950 does look impressive even at this early stage of clinical trials. I wouldn’t hold your breath but it looks worthy of keeping an eye on.
Data announced today by Vertex show that VX-950, an investigational hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a , achieved a […]